Full-Time
Prescription price comparison and coupons
No salary listed
Remote in USA
Remote
Remote within the United States.
JD
See people who can refer or advise you
GoodRx provides price comparisons, coupons, and discounts for prescription medications through its website and mobile app. It partners with pharmacies to offer savings at the point of sale, earning referral fees. It also offers GoodRx Gold subscription with deeper discounts and earns revenue from ads and partnerships. The goal is to save people money on prescriptions and improve access to affordable medicines.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Santa Monica, California
Founded
2005
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Medical, dental, and vision insurance
401(k) with a company match
ESPP
Unlimited vacation
"Take care of yourself" days
11 paid holidays
GoodRx is expanding beyond prescription savings as subscription revenue climbed 39% year over year. CEO Wendy Barnes told Yahoo Finance the company expects to return to top-line growth this year, earlier than anticipated, though at low single-digit rates. The platform maintains around 280 million site visits but is seeing shifts in user behaviour. There's been considerable increase in users seeking GLP-1 coverage as many employers don't cover these medications. Barnes said users are looking for longer-term value and the ability to fill their entire medicine cabinet rather than using multiple point solutions. Direct-to-pharma sales rose 76% year over year.
SEI Investments stands out as a profitable long-term investment opportunity, whilst GoodRx and The Hanover Insurance Group face headwinds, according to StockStory analysis. SEI Investments, which provides technology platforms and investment management solutions, boasts a 27.9% trailing 12-month GAAP operating margin. Founded in 1968, the company serves financial institutions, wealth managers, and investors. Meanwhile, GoodRx struggles with flat sales over two years and negative returns on capital, despite its 9.9% operating margin. The prescription drug price comparison platform has a modest revenue base of $787.9 million. The Hanover Insurance Group, with a 14.8% operating margin, faces challenges including below-standard revenue growth of 4.9% annually over two years and lacklustre policy growth of 4.2% yearly, underperforming typical financial institutions.
New 'GoodRx Companion' subscription targets rising costs. Fort Myers News-Press & Naples Daily News June 2, 2026, 5:07 a.m. ET * GoodRx has launched a new subscription program called GoodRx Companion for $14.99 per month. * The program offers savings on generic medications, online care visits, lab work, and dental and vision care. * This new service is a response to rising healthcare costs and inflation affecting American consumers. GoodRx, an online resource for discounted medications, has launched a membership program that ties in health-care services for consumers. There also is savings for dental and vision care, according to the Santa Monica, Calif-based online platform. The company says it helps nearly 25 million American consumers annually with discounts. "GoodRx Companion is an important step in our evolution toward building a broader subscription model built for the way consumers are navigating healthcare today," Wendy Barnes, president and chief executive officer of GoodRx, said in a news release. The offering comes as Americans see their budgets squeezed by inflation, and higher costs for health care. Many Americans lost what was called "enhanced" premium assistance at the end of 2025 for health insurance through Affordable Care Act. Congress did not reinstate the assistance in 2025 that became a primary cause for a 43-day government shutdown, the longest ever from Oct. 1 to mid November. The enhanced premium assistance were enacted in 2021 during COVID-19 pandemic disruptions. For many Americans to afford higher premiums this year for their ACA plans or even with employer-sponsored coverage, they've opted for higher deductibles and other out-of-pocket cost sharing. Can GoodRx Companion help you? GoodRx says its new service is an option to address health care affordability issues, Barnes said. "As coverage becomes more complex and out-of-pocket costs continue to rise, people are looking for trusted solutions that give them greater control and clearer value," she said. The company says it has tapped its pricing capabilities, retail pharmacy relationships, and consumer experience that it has built over more than a decade to launch the subscription service to make health care more affordable and predictable, according to the company. Since 2011, GoodRx says it has helped Americans save more than $100 billion on the cost of their medications. At the same time, the digital platform has been under scrutiny. In 2023, the Federal Trade Commission said GoodRx shared information about users' health conditions and prescription drugs with digital advertisers like Facebook and Google without permission and contrary to what it told users in its privacy policy. GoodRx settled with the federal agency that same year, agreeing to pay a $1.5 million civil penalty. It is prohibited from sharing users' health data with applicable third parties for advertising purposes. The company said it admitted no wrongdoing and said the FTC focused on an old issue that was proactively addressed three years before the government inquiry began. What do you get with GoodRx Companion? * Prescription savings: More than 200 common generic medications for free, with hundreds more for less than $10, available at nearly every pharmacy nationwide * Online care: $19 telehealth visits on GoodRx Care for common needs such as UTIs, skin care, flu, and other routine conditions * Dental care: Savings on cleanings, exams, X-rays, crowns, and other dental services * Vision care: Savings on eye exams, glasses, contact lenses, and laser eye surgery * Lab and imaging services: Significant savings on common lab and imaging services such as MRIs, CT scans, ultrasounds, comprehensive wellness labs, and hormone panels Do you have an opinion about this topic? Write a letter to the editor and send it [email protected] and/or [email protected]. Keep it to 250 words or fewer and include your contact info. Have more to say: Send a guest column of no more than 600 words. Liz Freeman is a health care reporter. Reach her by emailing [email protected] Please support local community journalism and stay informed about Southwest Florida news by subscribing to The News-Press and Naples Daily News; download the free News-Press or Naples Daily News app, and sign up for daily briefing email newsletter, food & dining and growth & development newsletters here and here.
GoodRx has launched GoodRx Companion, a $14.99 monthly subscription offering free and low-cost generic medications, affordable telehealth visits and savings on healthcare services. The programme provides over 200 common generic medications for free, hundreds more for under $10, $19 telehealth consultations and discounts on dental care, vision care and lab services. The subscription advances GoodRx's strategy to build recurring consumer relationships beyond individual prescription transactions, complementing its existing condition-focused offerings for weight loss, erectile dysfunction and hair loss. Chief executive Wendy Barnes said the launch addresses rising out-of-pocket healthcare costs and creates a more diversified membership model. GoodRx serves nearly 25 million consumers annually and has helped Americans save over $100 billion on medications since 2011.
GoodRx raised $120 million in a Series C round, with its stock rising following strong first-quarter results driven by its Pharma Direct segment, which grew 82% year-over-year. CEO Wendy Barnes credited investments in manufacturer-sponsored pricing programmes and weight loss subscriptions, particularly supporting GLP-1 therapy launches including the Wegovy Pill. The company reported revenue of $194 million, beating analyst estimates of $184.6 million, and raised full-year revenue guidance to $775 million from $765 million. However, revenue declined 4.4% year-over-year. Management acknowledged that prescription transaction revenue remains under pressure but emphasised that Pharma Direct and subscriptions provide more durable revenue streams. CFO Christopher McGinnis noted some cannibalization of core transactions is preferred given Pharma Direct's long-term sustainability.